Subsequently, we divided CD8+ TILs from NSCLC patients undergoing anti‐PD‐1 therapy into CD8+CSNK2Bhigh and CD8+CSNK2Blow groups, according to the level of CSNK2B expression. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.